Consistent with previous studies linking elevated CD73 levels to poor clinical outcomes in various tumor types, we found that higher CD73 expression in a variety of solid tumors including CRC was associated with shorter overall survival times (Fig. S1B–D), suggesting CD73 may serve as a prognostic marker for CRC patients. Here, NT5E is linked to neoplasm.